TNF and inflammatory bowel disease: There was a gradual increase in the prescription of anti-TNF biosimilars over the years, from 33% (17 of 51 IBD patients on anti-TNF) in 2018 to 67% (61 of 91 IBD patients on anti-TNF) in 2022.